PD-1/PD-L1 inhibitors have been successful in the therapy of cHL, which typically exhibits an overexpression of PD-1 ligands (PD-L1, PD-L2) due to near-universal genetic changes in chromosome locus 9p24.1 [54]. This evidence concerns the gene PDCD1LG2 and classic Hodgkin lymphoma.